Navigation Links
Genaera Corporation Announces Results of Special Meeting of Stockholders
Date:6/5/2009

PLYMOUTH MEETING, Pa., June 5 /PRNewswire-FirstCall/ -- Genaera Corporation ("the Company") (Nasdaq: GENR) today announced that proxies representing a majority of the shares voted at the Special Meeting of Stockholders on June 4, 2009 were cast in favor of the resolution to approve a Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution).

About Genaera

Genaera Corporation has developed trodusquemine (MSI-1436) for type 2 diabetes and obesity and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as from other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

www.genaera.com


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors
2. Genaera Corporation Implements Cash Conservation Plan
3. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
4. Genaera Corporation Announces 2008 Financial Results
5. Genaera to Present at BIO CEO & Investor Conference
6. Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
7. Genaera to Present at Therapeutic Area Partnerships 2008
8. Genaera Receives Non-Compliance Notice From NASDAQ
9. Genaera Corporations 2008 Annual Stockholder Meeting Results
10. Xmark Comments on Genaera Cost-Saving Plan
11. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North Hollywood ... of February, patients who visit Hamlin Dental Group will receive a ticket for a ... the Cheesecake Factory. , Tickets are available for routine dental visits and other ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an approved content provider for the National Institute for Health and Care ... social care-related organizations in the National Health Service (NHS) to search, order and ...
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data ... that Premier Research, a leading clinical development service provider, has selected ERT’s Trial ... complex, due in part to an array of circumstances including the use of ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize ... der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that it will release fourth quarter and yearly ... 2nd, 2017. AcelRx management will host an investment-community ... p.m. Pacific Time) on March 2 nd ...
Breaking Medicine Technology: